Key Drivers
- Strong gross margin
- Meaningful FCF
- Elevated leverage
AIAI Summary
Teleflex has shifted from a steady medical-device cash generator into an execution-dependent, capital‑intensive restructuring—upside now hinges on successful BIOTRONIK VI integration and timely NewCo monetization, so monitor quarter‑over‑quarter margin recovery, OCF conversion, and a credible NewCo pricing/timeline as the decisive catalysts. Failure to hit these milestones will likely exacerbate leverage risk and force multiple contraction.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong gross margin
- •Meaningful FCF
- •Elevated leverage
TFX shows strong cash generation and liquidity but is weighed down by steep losses, high debt and large intangibles that undermine returns and solvency.
Price Behavior
Key Price Behavior Insights:
- •Below last month SMA
- •Deeply oversold
- •Lower highs sequence
Stock has rolled from a short-term up-phase into a clear downtrend—closing at $105.41 well below the last month SMA (~$113.20) with deeply oversold momentum, making resistance near $122.57/$121.84 (and the ~$113 area) key for any trend repair.
Large mid-double-digit percent decline from early-March highs with
Sentiment & News
Key News Insights:
- •Revenue growth
- •Q4 miss & margins
- •Transition uncertainty
Teleflex delivered strong FY‑2025 revenue growth but missed Q4 consensus with margin compression amid post‑divestiture transition and mixed investor/analyst reactions.
Shares likely face near‑term volatility as solid top‑line performance and operational investments are balanced against margin pressure and transition-related earnings uncertainty
Similar Companies in Healthcare
Other companies in the same sector with AI ratings